Learn about or register for participation in future Department of Urology clinical research.
Phase II Study of Adenovirus/PSA Vaccine in Men with Recurrent or Hormone Refractory Prostate Cancer
The University of Iowa Department of Urology and the Holden Clinical Cancer Center are conducting a clinical research study of a gene therapy vaccine for recurrent prostate cancer.
We are seeking patients with recurrence of prostate cancer after surgery, radiation therapy, or hormonal treatment.
All prostate cancer patients who are interested in this study will be carefully screened for participation. Not all patients will qualify for this study.
Those selected to participate will receive three vaccinations (shots) 30 days apart, and will be watched closely for development of immune response to the vaccine and changes in their prostate cancer.
To learn more about enrolling in this clinical research study, please contact Pamela Zehr, Clinical Research Coordinator, at 319-353-8914, or email@example.com.